Hantavirus reveals a serious weakness: The next outbreak may not be profitable enough to stop

EU PERSPECTIVES - The latest hantavirus outbreak is forcing Europe to confront an uncomfortable reality: vaccines or treatments against some dangerous viruses may never reach the market. Not because the science is impossible, but because developing them is not commercially attractive for pharmaceutical companies. Brussels is increasingly preparing to fill that gap itself. Read more

The science to develop hantavirus vaccines already exist. The challenge is getting markets to invest in them / Photo: CDC, Unsplash